Overview

How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics

Status:
Completed

Trial end date:
2010-04-01

Target enrollment:

Participant gender:

Summary

This study is designed to look at how using glargine insulin with oral diabetes medications and exenatide may improve control of blood sugar levels and weight gain in type 2 diabetics. The main study will last 32 weeks. However, all participants completing 32 weeks will be invited to continue for another 24 weeks taking the insulin and oral medication and exenatide treatment. This extension comparing insulin and oral medication with insulin and oral medication and exenatide will look at the long term weight loss/gain and blood sugar level control effects of this new drug regimen. There is also a sub-study in the Clinical Research Center (CRC), which requires two 38-hour inpatient stays during the main study. This study offers the opportunity to study 24-hour blood sugar and metabolic patterns quantitatively.

Phase:

Phase 4

Details

Lead Sponsor:

Oregon Health and Science University

Collaborators:

Amylin Pharmaceuticals, LLC.
Eli Lilly and Company

Treatments:

Exenatide
Insulin
Insulin Glargine
Metformin